Figure 1. Daam2 is expressed in human glioma.

(A) Analysis of Daam2 RNA expression across a spectrum of cancers. Data was generated by TCGA Research Network and is publicly available (see methods). Box plots represent 5%, 25%, 50%, 75%, and 95%. Asterisk denotes tumor groups significantly higher (red) or lower (blue) as compared to corresponding non-tumor (‘normal’) group. P-values were generated by t-test on log-transformed data. (B) Examples of pathological grading of in situ hybridization analysis of Daam2 expression in human glioma tissue microarrays. Note that a score of 0 demonstrates no expression, while a score of 3 denotes very high expression. (C) Graded pathological scoring (0-low intensity, 3-high intensity) of Daam2 expression in the samples in B; values are the percentage of LGG and GBM tumors from the tissue microarray that were assigned respective score. (D) Immunohistochemistry analysis of Daam2-LacZ expression in mouse glioma generated in Daam2^LacZ/+ mice.

Figure 1—figure supplement 1. Daam2 is expressed in experimental models of human glioma.

(A) Tissue microarray showing in situ hybridization expression analysis of human DAAM2 across 35 LGG (red boxes) and 40 GBM (green boxes). Blue box denotes normal human brain samples. (B) qRT-PCR analysis of DAAM2 in primary human glioma samples and associated non-tumor, white matter. (C–H) Expression of DAAM2 in xenograft tumors generated from GBM1 and GBM2 cell lines. (D–E, G–H) high magnification images of in situ hybridization using antisense probes showing expression of Daam2 mRNA in these tumors. (C, F) Low magnification images of xenograft tumors from GBM1 and GBM2 cell lines showing widespread expression of Daam2 in these tumors. Scale bar in E is 50 nm and is applicable to D-E, G-H.